RxSight (RXST) Other Non Operating Income (2022 - 2023)

RxSight (RXST) posted Other Non Operating Income of -$1.4 million for Q3 2023, down 288.67% on a QoQ basis from -$362000.0 in Q2 2023.

RxSight (RXST) Other Non Operating Income (2022 - 2023) Analysis & Trends

RxSight's Other Non Operating Income history runs 2 years deep, the most recent figure standing at -$1.4 million for Q3 2023.

Quarterly Other Non Operating Income changed N/A year-over-year to -$1.4 million in Q3 2023, while the trailing twelve-month figure through Sep 2024 was -$1.4 million (down 181.4% YoY) and the FY2025 annual result came in at $272000.0, changed N/A from the prior year.
Other Non Operating Income was -$1.4 million for Q3 2023 at RxSight, down from -$362000.0 in the prior quarter.
Across five years, Other Non Operating Income topped out at $1.3 million in Q4 2022 and bottomed at -$1.4 million in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-
10	RxSight	221.81 Mn	-196.39 Mn	23.50 Mn

Download Data